Current tools for prediction of arteriovenous fistula outcomes


**Published in:**
Clinical kidney journal

**Document Version:**
Publisher's PDF, also known as Version of record

**Queen's University Belfast - Research Portal:**
Link to publication record in Queen's University Belfast Research Portal

**Publisher rights**
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

**General rights**
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

**Open Access**
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Download date:21. Oct. 2023
Current tools for prediction of arteriovenous fistula outcomes

Damian G. McGrogan, Alexander P. Maxwell, Aurang Z. Khawaja and Nicholas G. Inston

Department of Vascular Access and Renal Transplantation, University Hospitals Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TH, UK, Regional Nephrology Unit, Belfast Health and Social Care Trust, Belfast City Hospital, Belfast BT9 7AB, UK and School of Medicine, Dentistry and Biomedical Sciences, Health Sciences Building, Belfast BT9 7BL, UK

Correspondence to: Damian G. McGrogan; E-mail: damianmcg@gmail.com; damian.mcgrogan@uhb.nhs.uk

Abstract

It remains challenging to accurately predict whether an individual arteriovenous fistula (AVF) will mature and be useable for haemodialysis vascular access. Current best practice involves the use of routine clinical assessment and ultrasonography complemented by selective venography and magnetic resonance imaging. The purpose of this literature review is to describe current practices in relation to pre-operative assessment prior to AVF formation and highlight potential areas for future research to improve the clinical prediction of AVF outcomes.

Keywords: arteriovenous fistula; clinical assessment; definitions; ultrasonography; venography

Introduction

It remains challenging to accurately predict whether an individual arteriovenous fistula (AVF) will mature and be useable for haemodialysis vascular access. In part, this is due to the heterogeneity of end-stage renal disease (ESRD) populations studied as these have varied in terms of age structure, background ethnicity and the relative prevalence of different ESRD aetiologies. The natural history of AVF maturation is also confounded by multiple comorbid conditions, such as diabetes and peripheral vascular disease, which may be present in ESRD patients. The outcome (clinically usable AVF) is further impacted by variation in point-of-care management of AVFs, e.g. cannulation expertise. In order to study the effect any variable has on a given vascular access outcome, it is important to establish specific definitions. The fact that there are multiple definitions of vascular access outcomes (summarized in Table 1) makes it more difficult to compare published data from different centres and countries.

The Renal Association Vascular Access for Haemodialysis clinical practice guidelines have encouraged the earlier formation of AVFs in an attempt to reduce the number of ESRD patients commencing haemodialysis using a central venous catheter (CVC). Furthermore, in the UK, National Health Service best practice tariffs for haemodialysis promote the use of AVFs as renal units providing haemodialysis receive higher annual payments for those ESRD patients using an AVF (compared with patients with a CVC). These financial incentives coupled with the persistently high failure rate of AVFs support renewed efforts to identify pre-operative predictors of AVF outcomes. The purpose of this literature review is to describe current practices in relation to pre-operative assessment prior to AVF formation as summarized in Figure 1 and highlight potential areas for future research to improve the clinical prediction of AVF outcomes.

How AVF matures

Guidelines suggest attempting to create an AVF at the most appropriate distal arm site. In practice, this means choosing the more proximal radiocephalic site before considering a brachiocephalic AVF. If these sites are unsuitable then a brachiobasilic procedure or placement of an arteriovenous graft (AVG) may be most appropriate. A useable AVF can offer the haemodialysis patient a durable vascular access option which, in comparison to prolonged CVC dependence, is associated with a lower risk of bloodstream infection and central venous stenosis. The ideal AVF must achieve an adequate connection between the high-pressure arterial and low-pressure venous systems; bypassing the small capillary network of the palmar arch while maintaining arterial perfusion and venous drainage in the tissues distal from the site of creation. As a result of the arteriovenous anastomosis, pressure within the vein increases, causing dilatation and ‘arterialization’ of the anastomosed vein. A reflex increase in cardiac output allows for this distal tissue perfusion and maturation of the fistula which is frequently complemented by retrograde arterial flow. Where retrograde flow is excessive, steal syndrome may occur characterized by distal neuralgia and eventually peripheral limb ischaemia.

Poiseuille’s law (as shown in Equation (1)) describes essential determinants of blood flow which are related to perfusion pressure, blood vessel radius and length and the viscosity of blood. The maturation of an AVF is partly...
Pressure difference and uration is unknown, although female sex and thrombophilia (factor V Lieden and prothrombin G20210A mutations; trauma and puncture and the surgical creation of an AVF can lead to homocysteine, the success or failure of an AVF. the surgical procedure itself are important components of mal hyperplasia after AVF formation [10]. Endothelial dys-ESRD itself may contribute to the development of neointi- sclerosis and pre-existing neointimal thickening asso-
shown in Figure 2. Arterial disease in the form of arterio-
creased wall shear stress, therefore inhibiting the dilatation and in-
function can also impair the arterial response to increased
artery [9].

Fluid flow is only 40–50% of this prediction and therefore other mechanisms must be operating [8]. The increase in blood flow is achieved through increased antegrade arterial blood flow in addition to retrograde blood flow from the palmar arterial arch in ~75% of AVFs [4], decreased blood viscosity associated with the increase in flow rate and therefore reduction in wall shear stress and friction [8]. This occurs in combination with main-
tained antegrade flow throughout the cardiac cycle as opposed to retrograde flow seen in diastole in a normal artery [9].

Other processes are involved in AVF maturation as shown in Figure 2. Arterial disease in the form of arterio-
sclerosis and pre-existing neointimal thickening asso-
ciated with conditions such as diabetes, hypertension and ESRD itself may contribute to the development of neointimi-
hyperplasia after AVF formation [10]. Endothelial dys-
function can also impair the arterial response to increased wall shear stress, therefore inhibiting the dilatation and in-
creased flow rates required for AVF maturation [3]. Venous trauma and fibrosis caused by previous cannulation, vene-
puncture and the surgical creation of an AVF can lead to inabil-
ity of venous distension preventing flow-induced re-
modelling [11]. Pre-existing arterial or venous disease and the surgical procedure itself are important components of the success or failure of an AVF.

The effect of coagulation disorders (high factor VIII:C, homocysteine, fibrinogen, d-dimer; presence of antiphospho-
lipid antibodies and short thrombin time) and thrombophilia (factor V Lieden and prothrombin G20210A mutations; protein C and antithrombin activities; and protein S) on mat-
uration is unknown, although female sex and thrombophilia are independent risk factors for loss of primary patency [12]. A recent Cochrane systematic review on the use of antiplatelet agents in chronic kidney disease found that while there was an associated reduction in early thrombosis rates of AVF, this had no effect on suitability for dialysis sup-
porting other underlying reasons [13]. For the purposes of pre-operative evaluation, the presence of such factors may be important but are generally not modifiable or useful in individuals to plan access.

Pre-operative assessment

Clinical assessment
Clinical assessment of an ESRD patient’s suitability for AVF creation involves detailed history taking and appropriate physical examination as summarized in Table 2. The use of clinical assessment alone may provide sufficient assess-
ment in selected cases. Wells et al. [14] discuss the selective-
use of ultrasonographic vascular mapping in the evalua-
tion of patients prior to the start of haemodialysis. They indicate that for some patients, ultrasound vascular
mapping is unnecessary and allows patients to avoid any time delay associated with an extra clinic appointment for ultrasonography and also reduces overall costs associated
with preoperative assessment. They suggest that this facil-
itates the development of a ‘one stop shop’ whereby
patients undergo clinical assessment and surgery on the
same day. It could also be argued that training of vascular
access surgeons in the use of ultrasonographic techniques
specific to vascular access would also reduce the costs
incurred and time delays.

Patient and fistula selection
Age and gender are often natural discriminators. As with
many conditions, the average age of the population with
ESRD is increasing annually. Hod et al. [15] highlighted
that the important risk factors for AVF failure in those
older than 67 years of age are increasing age, female
gender, black race, diabetes, cardiac failure and a shorter
period of pre-ESRD nephrology care. Similarly, Miller et al. [16] have shown a lower AVF adequacy in women com-
pared with men which was unexplained by pre-operative
blood vessel diameters. Ng et al. [17] found from their
analysis of 2920 patients that AVGs, female gender, dia-
betes and advanced age were all associated with signifi-
cantly shorter primary AVF patency.
In a systematic review performed by Al-Jaishi et al., it was shown that the primary AVF failure rates were higher in more distal compared with proximal upper limb sites (primary failure rates of 28% for lower arm AVF and 20% for upper arm AVF \( P = 0.001 \)). Similarly, the primary AVF patency rates at 1 year were significantly worse in lower arm versus upper arm sites (55 versus 65% for lower and upper arm AVFs, respectively) [18]. Older age, female gender, presence of diabetes and distal AVFs have all been identified as risk factors for

<table>
<thead>
<tr>
<th>Clinical assessment</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doppler ultrasound</td>
<td>Readily available</td>
<td>May fail to identify vessels suitable for radiocephalic</td>
</tr>
<tr>
<td></td>
<td>Relatively cheap</td>
<td>Cannot identify central venous stenosis</td>
</tr>
<tr>
<td></td>
<td>Improves uptake of distal vessels</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Useful in preoperative and post operative setting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can assess endothelial response to reactive hyperaemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can assess venous distensability</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lends itself to computational modelling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Requires additional training</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can add to delay in proceeding to fistula formation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Venography</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Identifies central venous stenosis</td>
<td>Relatively expensive</td>
</tr>
<tr>
<td></td>
<td>DSA gold standard</td>
<td>Less readily available than DUS</td>
</tr>
<tr>
<td></td>
<td>MRV available for pre-dialysis patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can identify clinically occult veins</td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td></td>
<td>Can identify arterial and venous disease</td>
<td>Less readily available</td>
</tr>
<tr>
<td></td>
<td>Lends itself to computational modelling</td>
<td>Expensive</td>
</tr>
<tr>
<td>Arterial stiffness</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td></td>
<td>Associated with adverse cardiovascular outcomes in large prospective studies of patients with ESRD</td>
<td>No evidence of utility in vascular access</td>
</tr>
<tr>
<td>Endothelial dysfunction</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td></td>
<td>Reduced endothelial function in uraemia</td>
<td>No evidence of utility in vascular access</td>
</tr>
<tr>
<td></td>
<td>Reduced nitric oxide production</td>
<td></td>
</tr>
<tr>
<td>Biomarkers and AGEs</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td></td>
<td>Readily available</td>
<td>No evidence of utility in vascular access</td>
</tr>
<tr>
<td></td>
<td>Value in predicting outcome patients in end stage renal disease</td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 1.** Summary of advantages and disadvantages associated with preoperative assessment tools. DSA, digital subtraction angiography; MRV, magnetic resonance venography; DUS, Doppler ultrasound scan; MRI, magnetic resonance imaging; NSF, nephrogenic systemic fibrosis; ESRD, end-stage renal disease; AGE, advanced glycation end-products.
Malovrh [21] reported immediate AVF failure rates of 44% utility of arterial diameter in predicting AVF outcomes.

Patients being considered for vascular access formation [20]. Practice guidelines suggest the use of DUS assessment in all patients prior to AVF construction. This is used not only as a preoperative tool in assessing arterial and venous anatomy but also in post-operative monitoring of AVF maturation and ongoing AVF surveillance. DUS assessment does require more clinical skill, equipment and time to perform (compared with clinical examination alone), but it remains non-invasive, safe, has reproducible results and helps to identify clinically occult veins [19]. DUS allows for observation of arterial diameter, vessel wall thickness, wall alterations, blood vessel course, localization of any obstructive or stenotic lesions present and can also perform a functional assessment. The 2007 European Renal Best Practice guidelines suggest the use of DUS assessment in all patients being considered for vascular access formation [20].

A number of studies have been conducted to assess the utility of arterial diameter in predicting AVF outcomes. Malovrh [21] reported immediate AVF failure rates of 44% and early failure rates of 64% where radial arterial diameters were <1.5 mm on pre-operative DUS. This contrasts with immediate and early AVF failure rates of 8 and 17%, respectively, where radial arterial diameters were >1.5 mm [22]. These findings have been supported by Parmar et al. [22] who found arterial diameters of <1.5 mm had an AVF failure rate of 45% compared with 0% when radial arterial diameter was >1.5 mm. Wong et al. [23] found a significant difference at an arterial diameter cut-off of 1.6 mm. Silva et al. [24] proposed a cut-off of 2 mm for arterial diameter as they found this to be associated with a very low early AVF failure rate of 8% and an excellent 1-year AVF patency rate of 83%. AVF patency beyond 6 weeks is considered an important parameter in the analysis of AVF outcomes.

DUS can be used to assess the functional ability of the artery to dilate by using a reactive hyperaemia test. This is performed by asking the patient to clench their fist while observing the phasic flow via DUS. The patient then releases the fist and the arterial ‘reaction’ is measured. This simulates the change from high pressure to low pressure which occurs in AVF formation and therefore provides a surrogate measurement of how the artery will respond to the ‘stress’ of AVF surgery. Malovrh [19] demonstrated that an absence of reactive hyperaemia characterized by a resistance index of <0.7 on opening of the fist is predictive of immediate postoperative AVF failure. These findings have been challenged by Lockhart et al. [25] who found no difference in AVF outcomes, except in functional patency of AVFs in women and Wall et al. [26] who found no difference in primary functional AVF patency but a significant difference in secondary AVF patency following surgical revision. These studies do not lend themselves to direct comparison but do suggest that the ability of the artery to dilate plays a significant functional role in AVF maturation.

DUS is also used to assess the cephalic and basilic veins in the arm, including the venous wall, route, patency, calibre, distensability and collateral circuits. The ideal vein for AVF formation has a relatively straight course and should lie <6 mm from the skin surface [27].

Due to the superficial nature of the veins, transducer gel should be applied copiously to prevent excessive pressure on the vein in question and therefore underestimation of vein diameter. Several studies have suggested the ideal diameter of the vein to be used for AVF formation. Small veins of <1.6 mm in diameter are associated with a high risk of early AVF failure within 12 weeks [23]. Silva et al. [24] suggested a minimum diameter of 2.5 mm with a tourniquet applied, whereas Mendes et al. [28] suggest a minimum diameter of >2 mm.

Venous distensability is assessed by measuring the diameter of the vein before and after at least 2 min of tourniquet placement. This can be achieved by inflating a sphygmomanometer to 60 mmHg. The percentage increase in the size of the vein is then evaluated by ultrasound. Malovrh [29] found that venous distensability was predictive of outcomes since subsequently successful AVFs showed a mean percentage dilatation of 44% compared with only 11% in the unsuccessful AVF group. Lockhart et al. [30] similarly found DUS useful in the identification of suitable veins by concluding that veins with a luminal diameter of >2.5 mm and those smaller veins that dilated up to 2.5 mm with placement of a tourniquet were equally

---

**Table 2. Summary of clinical assessment prior to arteriovenous fistula formation**

<table>
<thead>
<tr>
<th>Clinical assessment for vascular access</th>
<th>Systemic factors</th>
<th>Local factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Patient demographies including age, sex, ethnicity</td>
<td>Surgical technique</td>
</tr>
<tr>
<td>Peripheral arterial assessment</td>
<td>Pre-existing disease profile including arteriosclerosis, atherosclerosis, cardiac performance</td>
<td>Arterial remodelling secondary to increased wall shear stress</td>
</tr>
<tr>
<td>Peripheral venous assessment</td>
<td>Endothelial responsiveness</td>
<td>Increased arterial flow rate</td>
</tr>
<tr>
<td>(performed with proximal tourniquet)</td>
<td>Thrombophilia</td>
<td>Establishment of laminar flow</td>
</tr>
</tbody>
</table>

---

**Fig. 2.** Summary of factors involved in AVF maturation.
suitable for AVF formation. The presence of accessory veins has also been suggested to be a factor in non-maturation of AVF. An accessory vein <5 cm from the anastomosis can alter the functionality of the AVF [23], while the size of the collaterals rather than their position may impact on the rate of AVF non-maturation [31].

A recent systematic review [32] has concluded that the use of pre-operative DUS is associated with a higher rate of commencing dialysis, but this association did not reach statistical significance and therefore additional novel predictors of AVF outcomes may help improve clinical management of ESRD patients. This systematic review conclusion is supported by Smith et al. [33] who randomized patients into either routine or selective preoperative ultrasound imaging. They reported that routine pre-operative does not reduce early failure rates, influence site of AVF formation or reduce complications concluding that routine preoperative imaging may not be necessary where clinical evaluation detects suitable anatomy for AVF formation.

A novel computational model has been suggested by Caroli et al. [34] which is completely automated, fast, involves operator-independent calculations and enables the observer to quantitatively estimate patient-specific post-operative blood flow volume change over different AVF configurations. This model uses preoperative vessel dimension and arterial blood flow volume measurements taken during ultrasound assessment as input parameters to predict postoperative diameters and blood flow volumes at different time points after surgery. The computational model was found to be accurate in predicting blood flow volumes in individual patients 40 days postoperatively with highly significant correlation for different AVFs. As Roy-Chaudhury et al. [35] comment, this is a step towards individualization of AVF creation and a good example of the multidisciplinary research collaboration necessary to achieve a significant impact on vascular access outcomes.

**Venography**

Digital subtraction venography is considered to be the gold standard for assessment of the venous system and has been investigated as a potential adjunct to pre-operative assessment of patients with ESRD referred for AVF formation. Traditional iodinated contrast can be used in patients who are being dialysed; however, in patients who are pre-dialysis, magnetic resonance venography had been shown to have acceptable sensitivity and specificity when compared with venography with good inter-observer correlation regarding imaging quality and strategy planning [36]. Gadolinium-based magnetic resonance contrast media are no longer considered safe for persons with chronic kidney disease because of the risk of nephrogenic systemic fibrosis [37]. Carbon dioxide-based venography is a promising alternative contrast choice for use in patients with advanced chronic kidney disease and ESRD [38].

Hyland et al. [39] have shown that venography is able to identify clinically occult veins which may be usable for AVF formation, a conclusion which is supported by Patel et al. [40] who found that while this imaging modality can identify a greater number of suitable veins, paradoxically, the combined use of DUS and venography was associated with a decreased AVF maturation rate. The 2007 European Best Practice Guidelines advocate central venous imaging for all patients with a history of CVC placement to identify central venous stenosis or occlusion prior to AVF formation [21].

**Magnetic resonance imaging**

Magnetic resonance angiography (MRA) has been shown to enable accurate detection of upper limb arterial and venous stenosis and occlusions prior to AVF creation [41]. These stenoses are undetectable by conventional DUS and therefore identification could potentially reduce the early AVF failure and non-maturation rate. The recognition of nephrogenic systemic fibrosis and its association with gadolinium-based contrast media has prompted comparison of contrast-enhanced versus non-contrast-enhanced MRA [42] (NCE-MRA) and shown that while image quality and vessel-to-background ratios were lower, NCE-MRA is a feasible alternative in patients with ESRD.

Merkx et al. [43] assessed the merits of NCE-MRA for predicting vascular access outcomes based around a computer model. Postoperative arm inflows were predicted by computer modelling following pre-operative NCE-MRA and compared with blood flow measurements assessed by DUS postoperatively. They concluded that NCE-MRA is able to provide geometrical details of arterial stenoses which could assist the vascular surgeon in AVF planning. This expensive and less readily available investigation is unlikely to replace clinic-based DUS in the assessment of patients for AVF formation but may have applications in patients with peripheral arterial disease, thrombosis or reduced arm inflows due to local stenoses or global narrowing within the arterial lumen. Another limitation of this method is the necessity for DUS assessment of venous diameters since NCE-MRA grossly overestimates venous diameters [44].

**Novel techniques for prediction of AVF outcomes**

**Assessment of arterial stiffness**

Arterial stiffness, which is common in patients with chronic kidney disease, refers to the distensability, compliance and elastic modulus of the arterial vascular system and can be measured locally, regionally and systemically. Aortic pulse wave velocity is considered the gold standard [45] for assessing arterial stiffness as it gives the clearest pathophysiological significance since the majority of the buffering of pulse waves occurs within the aorta. The pulse wave Vicorder™ (Smart Medical, Moreton-in-Marsh, UK) is a non-invasive, easy to learn and reproducible method of assessing stiffness along an arterial section. Although other systems exist to measure aortic pulse wave velocity such as the Sphygmocor™ system (AtCor Medical, West Ryde, NSW, Australia) and Complior™ apparatus (Artech Medical, Pantin, France), these require greater operator instruction and are more intrusive to patients as they require palpation and assessment at the femoral artery. Increased aortic pulse wave velocity has been independently associated with adverse cardiovascular outcomes in large prospective studies, including specifically patients with ESRD [46]. Assessment of arterial stiffness has yet to be extensively investigated in relation to AVF outcomes and is an area of interest for future research projects.

**Assessment of endothelial function**

The responsiveness of the endothelium is an important aspect of the remodelling required to establish a mature AVF. The endothelium acts as an interface between the blood and all other tissues in the body performing important roles in maintaining the vascular environment through...
release of agents that regulate vasomotor tone, inflammatory responses and homeostatic functions [46]. Nitric oxide is a potent vasodilator, inhibitor of thrombus formation, smooth muscle cell proliferation and platelet adhesion and aggregation [47]. The loss of the vasodilatory response and promotion of thrombosis, inflammation and cellular proliferation associated with endothelial dysfunction is a potentially worthwhile research topic, since these mechanisms are closely related to AVF maturation. A number of studies have linked endothelial dysfunction with uremia and reduced nitric oxide production in chronic renal disease [48]. Owens et al. [49] found evidence that impairment of endothelial function is associated with decreased arterial remodelling and final venous diameter attained at 3 months post-fistula formation.

Two methods of measuring endothelial dysfunction are flow-mediated dilatation (FMD) and peripheral arterial tonometry (PAT). FMD is the most well-established method of assessing endothelial function and is based on the reactive hyperaemic response following a period of occlusion with a tourniquet. Increased blood flow following release of the cuff causes increased wall shear stress, leading to release of nitric oxide and therefore vasodilatation [50]. Monitoring the response will give a surrogate marker of endothelial performance post-fistula formation and therefore guide vascular surgeons regarding patient suitability and vascular access site placement. PAT is a more recent development which uses pneumatic finger probes to measure the digital pulse wave amplitude when reactive hyperaemia is induced [51]. A recent study assessing the correlation between these two methods in healthy patients and patients with peripheral arterial disease concluded that there was no correlation between these two methods and that FMD is a more accurate measure of nitric oxide-induced endothelial function [52].

A novel method of assessing the hyperaemic response in patients undergoing AVF formation is the use of near-infrared spectroscopy. This is a non-invasive, continuous, real-time determination of chromophore concentration on the basis of spectrophotometric principles. In mammalian tissue there are three chromophores which demonstrate absorption spectra in the near-infrared range (800–1200 nm wavelength), namely haemoglobin and deoxyhaemoglobin, myoglobin and cytochrome oxidase. The result is a measurement of mixed arterial and venous oxygen concentrations within the tissue being studied which, if placed distal to the site of AVF planning, may provide new information about the physiological response to AVF formation and assist in AVF planning. Another alternative way to assess endothelial dysfunction is the use of laser Doppler flowmetry and imaging to measure cutaneous perfusion accompanied by iontophoresis of acetylcholine and sodium nitroprusside. Hansell et al. [53] found a significant correlation between FMD in the brachial artery and laser Doppler flowmetry in small cutaneous vessels supporting the systemic nature of endothelial dysfunction and that microvascular changes in the skin mimic macrovascular changes in the supplying artery.

**Biomarkers**

As yet, there have been no biomarkers identified as a useful adjunct to AVF planning. Biomarkers have been extensively investigated in ESRD patients focusing on their usefulness in prognosis, diagnostics, response to therapy and prevention of disease. Elevated fibroblast growth factor 23 and bone alkaline phosphatase have been identified as having prognostic value in predicting mortality in patient with ESRD-related bone mineral disease while elevated C-reactive protein, interleukin-6 and tumour necrosis factor levels are associated with increased mortality in ESRD patients [54]. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase and high circulating levels are associated with endothelial dysfunction and atherosclerosis in patients with pre-dialysis ESRD [55].

A number of inflammatory markers, such as interleukin-6, tumour necrosis factor-α and soluble P selectin, have been associated with adverse cardiovascular outcomes [56]; however, high-sensitivity CRP (hs-CRP) has the strongest association with cardiovascular outcomes [57]. It is reported that hs-CRP can destabilize nitric oxide synthase mRNA in endothelial cells [58], suggesting a correlation between high circulating levels of hs-CRP and endothelial dysfunction. Also, 13-hydroxyoctadecadienoic acid (13-HODE) has been found to decrease with age in patients undergoing coronary artery bypass grafting and has been associated with an increase in endothelial cell thrombogenicity [56]. Other surrogate markers of endothelial cell activation and inflammation have been proposed, including lipoprotein-associated phospholipase A2, CD40 receptor/CD40 ligand interaction, LOX-1 and direct measurements of circulating endothelial progenitor cells [59]. Further studies are required to establish if assessing biomarkers of baseline endothelial function in patients with ESRD is clinically useful either for prediction of AVF maturation or to target therapies to modify local vascular biology prior to AVF formation.

Creation of an AVF has been shown to have significant effects on atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). An increase in ANP was induced by volume loading and BNP release was stimulated by left ventricular diastolic dysfunction. Additionally, a positive relationship has been shown between MMP-2 gene expression in vein segments evaluated by gelatin zymography and western blotting and AVF maturation [60]. The maximal benefit from biomarkers may lie in the multi-marker approach as evidenced by the Olmsted study which reported that the combination of increased BNP with CRP levels enhanced the ability to predict risk of death compared with standard risk factors for mortality in heart failure [61].

Advanced glycation end-products (AGEs) have been implicated in the pathophysiology of vascular disease where they accumulate in the endothelial cell wall and disrupt cellular structure and function, including decreasing the bioavailability of nitrous oxide and alteration of cell surface structure from an anticoagulant to pro-coagulant state. In theory, reducing the burden of AGEs would offer a potential novel therapeutic option to improve vascular biology and potentially improve maturation of AVFs. There is experimental evidence that agents such as aminoguanidine, ALT-946, ALT-711, statins, pyridoxamine and dietary modifications can help to reduce AGE levels [62]. There is no convincing evidence yet that such therapies improve vascular access outcomes.

**Assisted maturation**

Several novel therapies have been proposed to assist AVF maturation, including the use of far-infrared (FIR) therapy [63]. FIR is a non-invasive therapeutic modality which has been reported to improve access flow rates and reduce the incidence of AVF malfunction in
haemodialysis patients. Primary balloon angioplasty has been shown to improve primary AVF patency rates for AVFs with venous diameters of <3 mm [64] and also in AVFs with venous diameters of ≤2 mm [65]. These conclusions have been supported by more recent data from Turmel-Rodrigues, suggesting that by using an aggressive, multi-disciplinary approach a non-maturing AVF can be identified, evaluated and salvaged [66]. An increased number of interventions required to assist maturation is however associated with reduced primary and secondary patency rates and a higher number of interventions to maintain patency [67].

Current studies

The Hemodialysis Fistula Maturation [68] study is currently underway in the USA. This is a multicentre prospective cohort study which is aiming to recruit 600 patients undergoing new AVF creation with a 4-year follow-up period. The primary outcome is unassisted clinical maturation. The results of this study are eagerly anticipated as this is the first, large-scale, adequately powered cohort to address many of the outstanding questions related to predictors of AVF outcomes. Further studies into vascular access outcomes include the ‘Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis’ (NCT02055131) and ‘The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas’ (NCT01685710) which will provide further information on the use of aspirin in varying doses and the use of glyceryl trinitrate patches applied 5 cm proximal from the site of vascular access surgery in the prevention of early stenoses.

Conclusion

The factors leading to failure of AVF maturation are still ill defined and there is a limited ability to predict surgical vascular outcomes. Clinical examination and DUS measurements are the mainstays of current preoperative assessment. Further studies into this under-researched area are currently underway and there are many opportunities to develop better tools to predict AVF outcomes.

Conflict of interest statement. None declared.

REFERENCES
